Immunogenicity of varicella zoster vaccine in pediatric liver transplantation
1
Issued Date
2022-01-01
Resource Type
ISSN
13288067
eISSN
1442200X
Scopus ID
2-s2.0-85128488334
Pubmed ID
34324244
Journal Title
Pediatrics International
Volume
64
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatrics International Vol.64 No.1 (2022)
Suggested Citation
Atjayutpokin T. Immunogenicity of varicella zoster vaccine in pediatric liver transplantation. Pediatrics International Vol.64 No.1 (2022). doi:10.1111/ped.14934 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/86603
Title
Immunogenicity of varicella zoster vaccine in pediatric liver transplantation
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Background: Pediatric liver transplant (LT) candidates often miss complete varicella-zoster virus (VZV) vaccination before LT. We aimed to evaluate the immunogenicity of two doses of VZV vaccines in pediatric LT candidates younger than 2 years and persistence of its immunogenicity after LT. Methods: Patients aged 9–24 months were enrolled before LT. The first dose of VZV vaccine was given at 9 months, and the second dose was given at between 1 to 3 months later, and at least 4 weeks before LT. Varicella-zoster IgG (VZG) was used to detect immunoglobulin G antibodies to VZV and was reported as a test value (TV). A test value ≥ 0.9 was considered as seropositive. TV was measured at enrollment, 1 month after the first and the second dose of VZV vaccine, before LT, and 3 and 6 months after LT. Results: Fourteen children were enrolled in this prospective cohort study. The median age at the first and the second dose of VZV vaccine was 11.5 months (IQR 9–12) and 13 months (IQR 12–33), respectively. The seroconversion rate was 66.7% (8/12) and 70% (7/10) after the first and second VZV vaccine doses, respectively. Seven of nine patients who underwent LT had two doses of VZV vaccine. Six patients were seropositive before LT, which persisted at 3 to 6 months after LT. Of two patients who received only one dose, TV was not detected after LT. Conclusions: The two doses of VZV vaccine appeared to be more immunogenic than one dose in pediatric LT candidates aged less than 2 years.